This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
by Zacks Equity Research
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
Why Earnings Season Could Be Great for Pharming Group (PHAR)
by Zacks Equity Research
Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
by Zacks Equity Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Pharming Group N.V. Sponsored ADR (PHAR) and POINT Biopharma Global Inc. (PNT) have performed compared to their sector so far this year.
Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.